GlassScriptPhysician profile
Vincent J Honan
NPI 1073585014
$10,562.00
in general payments reported to CMS, 2019-2025
36 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,226 · 2020: $1,380 · 2021: $2,345 · 2022: $2,108 · 2023: $2,187 · 2024: $124 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,806.66 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,686.54 | 2019-2023 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $704.61 | 2019-2023 | |
| Janssen Biotech, INC. | $672.47 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $667.55 | 2019-2025 | Entyvio |
| Pfizer INC. | $509.61 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $419.10 | 2020-2023 | |
| Celgene Corporation | $394.46 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $362.58 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $330.72 | 2019-2023 | Sucraid |
| Redhill Biopharma INC. | $293.17 | 2020-2022 | |
| Allergan, INC. | $201.64 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $188.92 | 2020-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $162.68 | 2021-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $160.98 | 2022-2023 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $156.72 | 2022-2023 | Ibsrela |
| Genzyme Corporation | $137.16 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $112.23 | 2019-2023 | Linzess |
| Daiichi Sankyo INC. | $89.85 | 2019-2021 | |
| Shionogi INC | $79.54 | 2019 | |
| Ucb, INC. | $69.83 | 2019 | |
| Alfasigma USA, INC. | $51.56 | 2020-2022 | |
| Intra-Sana Laboratories | $40.23 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Shire North American Group INC | $39.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $32.96 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $28.41 | 2021-2022 | |
| Lucid Diagnostics INC. | $24.11 | 2023 | |
| Fresenius Kabi USA, LLC | $23.29 | 2023 | |
| Boston Scientific Corporation | $22.19 | 2024 | Compliance Endokit |
| Organon LLC | $19.58 | 2023 | Hadlima |
| Evoke Pharma, INC. | $16.77 | 2020 | |
| Axonics, INC. | $15.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.20 | 2019 | |
| Braintree Laboratories, INC. | $13.99 | 2023 | Sutab |
| W. L. Gore & Associates, INC. | $11.95 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Honan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.